Mirum Pharmaceuticals Acquires Bluejay Therapeutics for $268.5M, Bolsters Rare Disease Portfolio
Event summary
- Mirum Pharmaceuticals completed the acquisition of Bluejay Therapeutics for a combination of cash and stock, with potential milestone payments.
- The deal includes worldwide rights to brelovitug, a late-stage monoclonal antibody for chronic hepatitis delta virus (HDV).
- Mirum raised $268.5 million in private placements to support clinical development and commercial activities post-acquisition.
- Topline data from the AZURE Phase 3 program for brelovitug is expected in the second half of 2026, with a potential BLA submission in 2027.
The big picture
Mirum’s acquisition of Bluejay Therapeutics strengthens its position in the rare disease space, particularly in liver conditions. The deal comes as the biotech industry continues to consolidate, with larger players acquiring specialized assets to expand their portfolios. The $268.5 million raised in private placements underscores investor confidence in Mirum’s ability to execute on its strategic vision, but the success of the acquisition will hinge on the clinical and commercial performance of brelovitug.
What we're watching
- Clinical Trial Success
- Whether brelovitug will meet primary endpoints in the AZURE Phase 3 program, given its strong Phase 2 results.
- Regulatory Pathway
- The pace at which the FDA and EMA will review brelovitug, considering its Breakthrough Therapy and PRIME designations.
- Integration Challenges
- How Mirum will integrate Bluejay’s team and assets, and whether the expected synergies will materialize.
Related topics